Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors


April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

April Rose, MD, assistant professor of oncology, Gerald Bronfman Department of Oncology, McGill University, discusses the efficacy results of the ongoing phase 2 BEAVER trial (NCT03839342) in non-V600E BRAF-mutant advanced solid tumors.

The BEAVER trial is an open-label, single-center study examining the use of binimetinib (Mektovi) plus encorafenib (Braftovi) in adult patients with advanced and/or metastatic solid tumors that harbor non-V600E BRAF mutations. Patients were a median age of 61 years and the majority had received at least 2 systemic therapies, Rose explains. Patients with a variety of different cancer types were enrolled on the study, including melanoma, colorectal, pancreatic, gallbladder, ampullary, breast, non–small cell lung, and uterine cancers, Rose adds.

Regarding efficacy, 2 of 11 patients responded with the combination of binimetinib and encorafenib, Rose continues. Additionally, 2 patients achieved stable disease, whereas all remaining patients developed progressive disease. This translated to an overall response rate of 18%, Rose concludes.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic